Rani Therapeutics, RxSight: 2 Bullish Health Care Stock Picks From BofA
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI), an early stage platform technology company that promotes oral dosing with its RaniPill, and RxSight, Inc.
JP Morgan Initiates Coverage On RxSight with Overweight Rating, Announces Price Target of $16
JP Morgan analyst Robbie Marcus initiates coverage on RxSight (NASDAQ:RXST) with a Overweight rating and announces Price Target of $16.
B of A Securities Initiates Coverage On RxSight with Buy Rating, Announces Price Target of $17
B of A Securities initiates coverage on RxSight (NASDAQ:RXST) with a Buy rating and announces Price Target of $17.
BTIG Initiates Coverage On RxSight with Buy Rating, Announces Price Target of $28
BTIG analyst Ryan Zimmerman initiates coverage on RxSight (NASDAQ:RXST) with a Buy rating and announces Price Target of $28.
Wells Fargo Initiates Coverage On RxSight with Overweight Rating, Announces Price Target of $20
Wells Fargo analyst Larry Biegelsen initiates coverage on RxSight (NASDAQ:RXST) with a Overweight rating and announces Price Target of $20.
SVB Leerink Initiates Coverage On RxSight with Outperform Rating, Announces Price Target of $20
SVB Leerink analyst Richard Newitter initiates coverage on RxSight (NASDAQ:RXST) with a Outperform rating and announces Price Target of $20.
The Week Ahead In Biotech: Cara FDA Decision, Ascendis Earnings, Aileron Data Presentation And More
Biotech stocks swayed back and forth before ending the week lower. With earnings news dying down and an empty initial public offerings calendar, it was broader market cues, clinical readouts and regulatory actions that moved stocks during the week.
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen’s Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios’ Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 17)